Multicenter evaluation of the Verigene Gram-Negative Blood Culture Nucleic Acid Test on the impact of resistance gene determinant for the prediction of susceptibility of Enterobacteriaceae to third-generation cephalosporin in Japan

Multicenter evaluation of the Verigene Gram-Negative Blood Culture Nucleic Acid Test on the impact of resistance gene determinant for the prediction of susceptibility of Enterobacteriaceae to third-generation cephalosporin in Japan - Gram negative bacteremia (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca or Proteus spp.)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018119

Enrollment

100

Registered

2015-06-30

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram negative bacteremia (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca or Proteus spp.)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (i)Tsukuba Medical Center Hospital The blood of Gram negative bacteremia detected by the BacT/ALERT 3D system (ii)Other hospitals or the Miroku Medical Laboratory Strains of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca or Proteus spp. without in vitro susceptibility to third-generation cephalosporin (cefotaxime MIC = 2ug/mL or more) isolated from the blood of positive blood culture bottles incubated by automated blood culture systems.

Exclusion criteria

Exclusion criteria: (i) If strains and patient information are not available for clinical research purpose (ii) If evaluation with Verigene system is not able to be performed

Design outcomes

Primary

Measure	Time frame
Cefotaxime susceptibility of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus spp. when resistance genes are not detected by Verigene system with BC-GN panel	—

Secondary

Measure	Time frame
(i)Susceptibility of each Enterobacteriaceae to cefotaxime when resistance genes are not detected by Verigene system with BC-GN panel (ii)Detection rate of resistance genes by Verigene BC-GN panel among each Enterobacteriaceae with non-susceptible to cefotaxime (iii)Antimicrobial susceptibilities of each Enterobacteriaceae when blaCTX-M is detected by Verigene system with BC-GN panel	—

Countries

Japan

Contacts

Public ContactHiromichi Suzuki

Tsukuba Medical Center Hospital Division of Infectious Diseases, Department of Medicine/Department of Clinical Laboratory Medicine

hsuzuki@tmch.or.jp81-29-851-3511

Outcome results